Health-related quality of life among prescription opioid-dependent patients: Results from a multi-site study
2015; Wiley; Volume: 24; Issue: 4 Linguagem: Inglês
10.1111/ajad.12188
ISSN1521-0391
AutoresMargaret L. Griffin, Heather E. Bennett, Garrett M. Fitzmaurice, Kevin P. Hill, Scott E. Provost, Roger D. Weiss,
Tópico(s)Mental Health Treatment and Access
ResumoThe American Journal on AddictionsVolume 24, Issue 4 p. 308-314 Regular Article Health-related quality of life among prescription opioid-dependent patients: Results from a multi-site study Margaret L. Griffin PhD, Corresponding Author Margaret L. Griffin PhD Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts Department of Psychiatry, Harvard Medical School, Boston, Massachusetts Address correspondence to Margaret L. Griffin, Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill St., Belmont, MA 02478, USA. Email: mgriffin@mclean.harvard.eduSearch for more papers by this authorHeather E. Bennett BA, Heather E. Bennett BA Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MassachusettsSearch for more papers by this authorGarrett M. Fitzmaurice ScD, Garrett M. Fitzmaurice ScD Laboratory for Psychiatric Biostatistics, McLean Hospital, Belmont, Massachusetts Department of Biostatistics, Harvard School of Public Health, Boston, MassachusettsSearch for more papers by this authorKevin P. Hill MD, MHS, Kevin P. Hill MD, MHS Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts Department of Psychiatry, Harvard Medical School, Boston, MassachusettsSearch for more papers by this authorScott E. Provost MSW, MM, Corresponding Author Scott E. Provost MSW, MM Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts Address correspondence to Margaret L. Griffin, Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill St., Belmont, MA 02478, USA. Email: mgriffin@mclean.harvard.eduSearch for more papers by this authorRoger D. Weiss MD, Roger D. Weiss MD Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts Department of Psychiatry, Harvard Medical School, Boston, MassachusettsSearch for more papers by this author Margaret L. Griffin PhD, Corresponding Author Margaret L. Griffin PhD Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts Department of Psychiatry, Harvard Medical School, Boston, Massachusetts Address correspondence to Margaret L. Griffin, Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill St., Belmont, MA 02478, USA. Email: mgriffin@mclean.harvard.eduSearch for more papers by this authorHeather E. Bennett BA, Heather E. Bennett BA Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MassachusettsSearch for more papers by this authorGarrett M. Fitzmaurice ScD, Garrett M. Fitzmaurice ScD Laboratory for Psychiatric Biostatistics, McLean Hospital, Belmont, Massachusetts Department of Biostatistics, Harvard School of Public Health, Boston, MassachusettsSearch for more papers by this authorKevin P. Hill MD, MHS, Kevin P. Hill MD, MHS Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts Department of Psychiatry, Harvard Medical School, Boston, MassachusettsSearch for more papers by this authorScott E. Provost MSW, MM, Corresponding Author Scott E. Provost MSW, MM Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts Address correspondence to Margaret L. Griffin, Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill St., Belmont, MA 02478, USA. Email: mgriffin@mclean.harvard.eduSearch for more papers by this authorRoger D. Weiss MD, Roger D. Weiss MD Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts Department of Psychiatry, Harvard Medical School, Boston, MassachusettsSearch for more papers by this author First published: 24 March 2015 https://doi.org/10.1111/ajad.12188Citations: 29Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Background Although prescription opioid use disorder has recently increased sharply in the United States, relatively little is known about the general well-being of this population. Assessment of quality of life in patients with substance use disorders has been recommended to improve clinical care. Objectives Health-related quality of life was examined in prescription opioid-dependent patients at entry to a national multi-site clinical trial, to compare quality of life scores in the study sample to other populations; further, background variables associated with quality of life in the literature were examined. Methods Prescription opioid-dependent patients (N = 653) were compared to general populations on the Medical Outcome Study Short Form-36 (SF-36) quality of life measure; and the association between patient background variables and quality of life was examined. Results Compared to a general population, the current sample of prescription opioid-dependent patients had worse physical (−1.7 points, p < .001) and mental quality of life (−12.3 points, p < .001) as measured by the SF-36, similar to other opioid-use disorder populations. Within our sample, women showed more impairment than men in mental quality of life (−4.3 points, p < .001); older patients scored worse on physical (−5.2 points, p < .001), but not mental, quality of life. Chronic pain was associated with poorer physical quality of life (−9.0 points, p < .001). Conclusions and scientific significance The growing focus on wellness underscores the importance of measuring quality of life in addition to substance use outcomes. Routine assessment of health-related quality of life can add an important dimension to overall evaluation of patients' treatment response. (Am J Addict 2014;XX:1 –7) Citing Literature Volume24, Issue4June 2015Pages 308-314 RelatedInformation
Referência(s)